Our data also suggests that breast cancers containing high levels of HIF-1 and reduced DUSP2 expression could be utilized as predictive markers for lapatinib-resistance and identify patient population that may benefit from combination treatment with lapatinib and MEK inhibitors for the treatment of hypoxic ERBB2-positive tumors. Here, ERBB2 is linked to breast cancer.